Cargando…

Phenotype-independent DNA methylation changes in prostate cancer

BACKGROUND: Human prostate cancers display numerous DNA methylation changes compared to normal tissue samples. However, definitive identification of features related to the cells’ malignant status has been compromised by the predominance of cells with luminal features in prostate cancers. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellacani, Davide, Droop, Alastair P., Frame, Fiona M., Simms, Matthew S., Mann, Vincent M., Collins, Anne T., Eaves, Connie J., Maitland, Norman J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219500/
https://www.ncbi.nlm.nih.gov/pubmed/30318509
http://dx.doi.org/10.1038/s41416-018-0236-1
_version_ 1783368665021808640
author Pellacani, Davide
Droop, Alastair P.
Frame, Fiona M.
Simms, Matthew S.
Mann, Vincent M.
Collins, Anne T.
Eaves, Connie J.
Maitland, Norman J.
author_facet Pellacani, Davide
Droop, Alastair P.
Frame, Fiona M.
Simms, Matthew S.
Mann, Vincent M.
Collins, Anne T.
Eaves, Connie J.
Maitland, Norman J.
author_sort Pellacani, Davide
collection PubMed
description BACKGROUND: Human prostate cancers display numerous DNA methylation changes compared to normal tissue samples. However, definitive identification of features related to the cells’ malignant status has been compromised by the predominance of cells with luminal features in prostate cancers. METHODS: We generated genome-wide DNA methylation profiles of cell subpopulations with basal or luminal features isolated from matched prostate cancer and normal tissue samples. RESULTS: Many frequent DNA methylation changes previously attributed to prostate cancers are here identified as differences between luminal and basal cells in both normal and cancer samples. We also identified changes unique to each of the two cancer subpopulations. Those specific to cancer luminal cells were associated with regulation of metabolic processes, cell proliferation and epithelial development. Within the prostate cancer TCGA dataset, these changes were able to distinguish not only cancers from normal samples, but also organ-confined cancers from those with extraprostatic extensions. Using changes present in both basal and luminal cancer cells, we derived a new 17-CpG prostate cancer signature with high predictive power in the TCGA dataset. CONCLUSIONS: This study demonstrates the importance of comparing phenotypically matched prostate cell populations from normal and cancer tissues to unmask biologically and clinically relevant DNA methylation changes.
format Online
Article
Text
id pubmed-6219500
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62195002020-01-16 Phenotype-independent DNA methylation changes in prostate cancer Pellacani, Davide Droop, Alastair P. Frame, Fiona M. Simms, Matthew S. Mann, Vincent M. Collins, Anne T. Eaves, Connie J. Maitland, Norman J. Br J Cancer Article BACKGROUND: Human prostate cancers display numerous DNA methylation changes compared to normal tissue samples. However, definitive identification of features related to the cells’ malignant status has been compromised by the predominance of cells with luminal features in prostate cancers. METHODS: We generated genome-wide DNA methylation profiles of cell subpopulations with basal or luminal features isolated from matched prostate cancer and normal tissue samples. RESULTS: Many frequent DNA methylation changes previously attributed to prostate cancers are here identified as differences between luminal and basal cells in both normal and cancer samples. We also identified changes unique to each of the two cancer subpopulations. Those specific to cancer luminal cells were associated with regulation of metabolic processes, cell proliferation and epithelial development. Within the prostate cancer TCGA dataset, these changes were able to distinguish not only cancers from normal samples, but also organ-confined cancers from those with extraprostatic extensions. Using changes present in both basal and luminal cancer cells, we derived a new 17-CpG prostate cancer signature with high predictive power in the TCGA dataset. CONCLUSIONS: This study demonstrates the importance of comparing phenotypically matched prostate cell populations from normal and cancer tissues to unmask biologically and clinically relevant DNA methylation changes. Nature Publishing Group UK 2018-10-15 2018-10-30 /pmc/articles/PMC6219500/ /pubmed/30318509 http://dx.doi.org/10.1038/s41416-018-0236-1 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Article
Pellacani, Davide
Droop, Alastair P.
Frame, Fiona M.
Simms, Matthew S.
Mann, Vincent M.
Collins, Anne T.
Eaves, Connie J.
Maitland, Norman J.
Phenotype-independent DNA methylation changes in prostate cancer
title Phenotype-independent DNA methylation changes in prostate cancer
title_full Phenotype-independent DNA methylation changes in prostate cancer
title_fullStr Phenotype-independent DNA methylation changes in prostate cancer
title_full_unstemmed Phenotype-independent DNA methylation changes in prostate cancer
title_short Phenotype-independent DNA methylation changes in prostate cancer
title_sort phenotype-independent dna methylation changes in prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219500/
https://www.ncbi.nlm.nih.gov/pubmed/30318509
http://dx.doi.org/10.1038/s41416-018-0236-1
work_keys_str_mv AT pellacanidavide phenotypeindependentdnamethylationchangesinprostatecancer
AT droopalastairp phenotypeindependentdnamethylationchangesinprostatecancer
AT framefionam phenotypeindependentdnamethylationchangesinprostatecancer
AT simmsmatthews phenotypeindependentdnamethylationchangesinprostatecancer
AT mannvincentm phenotypeindependentdnamethylationchangesinprostatecancer
AT collinsannet phenotypeindependentdnamethylationchangesinprostatecancer
AT eavesconniej phenotypeindependentdnamethylationchangesinprostatecancer
AT maitlandnormanj phenotypeindependentdnamethylationchangesinprostatecancer